<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30203335</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>05</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-0584</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>12</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Annals of hematology</Title>                <ISOAbbreviation>Ann. Hematol.</ISOAbbreviation>            </Journal>            <ArticleTitle>A monocentric retrospective study of 138 therapy-related myeloid neoplasms.</ArticleTitle>            <Pagination>                <MedlinePgn>2319-2324</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00277-018-3462-y</ELocationID>            <Abstract>                <AbstractText>As diagnosing therapy-related myeloid neoplasms (t-MN) is often challenging, we reviewed clinicopathological features of t-MN patients. Medical records of 138 patients, diagnosed with t-MN between 1995 and 2017, were reviewed. Of 138 patients, 80 had t-MDS, 53 t-AML, and 5 t-MDS/MPN (age, 22-88 years; median 64 years; male/female ratio, 0.8). The median latency time was 6 years and 5 months. Of 115 patients, 56 patients received cytotoxic-/radiotherapy for a solid tumor, 56 for hematological malignancy, and 3 for an auto-immune disorder, respectively. Another 21 patients had a combination of 2 disorders. Moreover, 2 patients had 3 previous malignancies. Breast cancer was the most prevalent tumor, followed by low-grade B non-Hodgkin lymphoma. Immunophenotyping and immunohistochemistry showed aberrant expression of B-, T-, or NK-cell markers in 21% and 6%, respectively. In 90% of the patients, dysplasia in ≥ 1 lineage was found. KMT2A fusion gene transcripts were seen in 5%. Cytogenetic analysis showed complex karyotypes (31%) and chromosome 5 and/or 7 abnormalities (40%). Almost 82% of the patients died and the median overall survival was about 1 year. Our study confirms that previous therapy for breast cancer is the most important cause of t-MN. KMT2A fusion genes are prevalent and complex karyotypes and/or chromosomes 5 and/or 7 abnormalities are common.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Claerhout</LastName>                    <ForeName>Helena</ForeName>                    <Initials>H</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9637-5592</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. helena.claerhout@uzleuven.be.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lierman</LastName>                    <ForeName>Els</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Human Genetics, University Hospitals Leuven and KU Leuven, Leuven, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Michaux</LastName>                    <ForeName>Lucienne</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Human Genetics, University Hospitals Leuven and KU Leuven, Leuven, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Verhoef</LastName>                    <ForeName>Gregor</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, University Hospitals Leuven, Leuven, Belgium.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, KU Leuven, Leuven, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Boeckx</LastName>                    <ForeName>Nancy</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, KU Leuven, Leuven, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Ann Hematol</MedlineTA>            <NlmUniqueID>9107334</NlmUniqueID>            <ISSNLinking>0939-5555</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C497422">MLL protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015514">Oncogene Proteins, Fusion</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>149025-06-9</RegistryNumber>                <NameOfSubstance UI="D051788">Myeloid-Lymphoid Leukemia Protein</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.1.1.43</RegistryNumber>                <NameOfSubstance UI="D011495">Histone-Lysine N-Methyltransferase</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002869" MajorTopicYN="N">Chromosome Aberrations</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019337" MajorTopicYN="Y">Hematologic Neoplasms</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011495" MajorTopicYN="N">Histone-Lysine N-Methyltransferase</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051788" MajorTopicYN="N">Myeloid-Lymphoid Leukemia Protein</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009196" MajorTopicYN="Y">Myeloproliferative Disorders</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016609" MajorTopicYN="Y">Neoplasms, Second Primary</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015514" MajorTopicYN="N">Oncogene Proteins, Fusion</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Retrospective study</Keyword>            <Keyword MajorTopicYN="N">Therapy-related myeloid neoplasm</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30203335</ArticleId>            <ArticleId IdType="doi">10.1007/s00277-018-3462-y</ArticleId>            <ArticleId IdType="pii">10.1007/s00277-018-3462-y</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>